Singapore – MGI Tech Co., Ltd. (“MGI”), a company dedicated to developing core tools and technologies that drive innovation in life sciences, today unveiled its new Customer Experience Center (CEC) in Singapore, its first in Southeast Asia, following successful launches in São Paulo, Brazil, and Berlin, Germany, the previous year. The new CEC reinforces MGI’s commitment to empowering researchers and institutions across the Asia-Pacific region with localized support and hands-on access to advanced genetic sequencing and spatial multi-omics solutions.

MGI Singapore
Located in Biopolis, Singapore’s leading biomedical R&D hub, the new CEC is designed as an innovative platform to accelerate scientific breakthroughs using MGI’s leading-edge sequencing technologies. The centre spans approximately 200 m² and houses four core laboratories—STOmics, sequencing, sample preparation, and single-cell labs—each equipped with MGI’s flagship product portfolio to support advanced research programs and foster cross-lab collaboration in the region. The facility will also showcase prototypes of upcoming MGI products, enabling partners across Asia-Pacific to gain early access and co-develop new applications.

The opening of the Singapore CEC underscores MGI’s continued investment in life sciences research and translational progress in Southeast Asia. To date, MGI has established collaborations with key Singapore-based partners, including MiRXES, the National Cancer Centre Singapore, and Nalagenetics, while extending its presence in Thailand, Vietnam, and Indonesia to broaden local access to its technologies.

ImmunoQs, a Singapore-based techbio company providing advanced spatial omics and data analytics services for cancer biomarker discovery and applications, is a key collaborator of MGI’s Singapore CEC. Building on a partnership dating back to 2024, MGI aims to support ImmunoQs with the new CEC’s spatial omics capabilities to advance research and clinical applications of spatial multi-omics technologies in cancer treatment.

“We are thrilled to be deepening our relationship with MGI through the new CEC,” said Dr. Loo Lit Hsin, CEO & Co-founder of ImmunoQs. “This state-of-the-art center provides local scientists with convenient access to world-class spatiotemporal omics technologies. We are confident that our collaboration with MGI will accelerate the integration of spatial multi-omics and deep analytical insights into cancer research, bringing us closer to more effective therapeutic solutions.”

“Singapore stands as a vital hub for life sciences innovation in Asia,” said Duncan Yu, President of MGI. “This center aims to place advanced omics tools directly into the hands of scientific pioneers who are pushing the boundaries of technology, furthering their exploratory research and discovery. The Singapore CEC will serve as a nexus for collaboration and innovation, connecting top-tier laboratories and research institutions in the region to advance the translation of scientific achievements and drive progress in global life sciences together.”

As of 30 September 2025, MGI has established a global network of CECs across key markets, including China, the UK, Australia, Germany, Brazil, Japan, and South Korea. The new Singapore CEC expands this network and reflects MGI’s ongoing commitment to making cutting-edge innovation more accessible, benefitting the global scientific community.